Postmortem analysis of quetiapine and pregabalin in human bone.


Journal

Legal medicine (Tokyo, Japan)
ISSN: 1873-4162
Titre abrégé: Leg Med (Tokyo)
Pays: Ireland
ID NLM: 100889186

Informations de publication

Date de publication:
Sep 2020
Historique:
received: 24 10 2019
revised: 11 03 2020
accepted: 06 05 2020
pubmed: 23 5 2020
medline: 8 9 2020
entrez: 23 5 2020
Statut: ppublish

Résumé

In this study quetiapine and pregabalin were analyzed in human bones. A method previously developed for the determination of antidepressants in human bone was tested for the analysis of these two substances. Bones were pulverized and subjected to the extraction protocol, and after undergoing solid-phase extraction, samples were analyzed using gas chromatography-mass spectrometry. The assay was validated in the range 0.3-500 ng/mg, mean analytical recovery was 76.9% for quetiapine and 90.9% for pregabalin, matrix effect was 83% for quetiapine and 91% for pregabalin and process efficiency was 63.8% for quetiapine and 82.7% for pregabalin. The intra- and inter-day precision was below 3% in all cases and the intra- and inter-assay accuracy values were in almost all cases better than 12%. The validated method was then applied to bone samples from forensic cases. Drugs were detected in bone in 2 of the 3 blood positive cases. The approximate concentrations in bone were 40 ng/mg for pregabalin and 7 ng/mg for quetiapine. To our knowledge, this is the first time these substances were detected in bones. With this study the number of substances with a validated protocol to be used in human bones in case of necessity is expanded.

Identifiants

pubmed: 32442861
pii: S1344-6223(20)30051-1
doi: 10.1016/j.legalmed.2020.101717
pii:
doi:

Substances chimiques

Antidepressive Agents 0
Quetiapine Fumarate 2S3PL1B6UJ
Pregabalin 55JG375S6M

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

101717

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Lucia Fernandez-Lopez (L)

Legal and Forensic Medicine, School of Medicine, University of Murcia, Murcia, Spain. Electronic address: lucia.fernandez2@um.es.

Rosanna Mancini (R)

National Centre on Drug Addiction and Doping, Istituto Superiore di Sanità, Rome, Italy.

Manuela Pellegrini (M)

National Centre on Drug Addiction and Doping, Istituto Superiore di Sanità, Rome, Italy.

Maria Concetta Rotolo (M)

National Centre on Drug Addiction and Doping, Istituto Superiore di Sanità, Rome, Italy.

Aurelio Luna (A)

Legal and Forensic Medicine, School of Medicine, University of Murcia, Murcia, Spain.

Maria Falcon (M)

Legal and Forensic Medicine, School of Medicine, University of Murcia, Murcia, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH